AFP and neoplasm: Both recurrence-free and overall survival rates were significantly lower in patients with persistent elevations of AFP, DCP, and cAFP-L3, respectively, before and after hepatectomy (group C) than in both patients without elevation of tumor markers (preoperatively and postoperatively, group A) and patients whose pretreatment tumor marker levels elevated but normalized after hepatectomy (group B).